dose-optimization

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα…

2 months ago